WINDLAS BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 632.1 INR | +0.29% |
|
+2.25% | +47.43% |
| 05-20 | Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
| 05-20 | Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 4,578 | 4,715 |
| Enterprise Value (EV) 1 | 2,884 | 3,445 |
| P/E ratio | 11.3 x | 11.4 x |
| Yield | 1.67% | 1.78% |
| Capitalization / Revenue | 0.98 x | 0.92 x |
| EV / Revenue | 0.62 x | 0.67 x |
| EV / EBITDA | 5.59 x | 5.87 x |
| EV / FCF | -17,215,837 x | -27,664,727 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.16 x | 1.17 x |
| Nbr of stocks (in thousands) | 21,794 | 20,927 |
| Reference price 2 | 210.0 | 225.3 |
| Announcement Date | 22-08-26 | 23-08-18 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,522 | 3,073 | 3,289 | 4,276 | 4,659 | 5,131 |
| EBITDA 1 | 396.4 | 395.8 | 405.7 | 552.3 | 515.5 | 586.9 |
| EBIT 1 | 237.8 | 301.4 | 322.1 | 434.1 | 402.8 | 478.7 |
| Operating Margin | 6.75% | 9.81% | 9.79% | 10.15% | 8.64% | 9.33% |
| Earnings before Tax (EBT) 1 | 198.5 | 761.2 | 246.7 | 217.4 | 455.6 | 570.4 |
| Net income 1 | 112 | 638.2 | 162.1 | 158.3 | 380.9 | 426.3 |
| Net margin | 3.18% | 20.77% | 4.93% | 3.7% | 8.17% | 8.31% |
| EPS 2 | 6.800 | 37.65 | 8.900 | 8.695 | 18.58 | 19.70 |
| Free Cash Flow | - | 109.6 | -15.56 | -154.3 | -167.5 | -124.5 |
| FCF margin | - | 3.57% | -0.47% | -3.61% | -3.6% | -2.43% |
| FCF Conversion (EBITDA) | - | 27.68% | - | - | - | - |
| FCF Conversion (Net income) | - | 17.17% | - | - | - | - |
| Dividend per Share | - | - | - | - | 3.500 | 4.000 |
| Announcement Date | 21-05-17 | 21-05-17 | 21-05-17 | 21-07-30 | 22-08-26 | 23-08-18 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 274 | - | - | - | - | - |
| Net Cash position 1 | - | 22.5 | 117 | 219 | 1,694 | 1,270 |
| Leverage (Debt/EBITDA) | 0.6908 x | - | - | - | - | - |
| Free Cash Flow | - | 110 | -15.6 | -154 | -168 | -125 |
| ROE (net income / shareholders' equity) | - | 40.1% | 8.04% | 7.62% | 12.8% | 10.7% |
| ROA (Net income/ Total Assets) | - | 6.41% | 6.32% | 8.55% | 6.4% | 5.87% |
| Assets 1 | - | 9,962 | 2,564 | 1,851 | 5,955 | 7,266 |
| Book Value Per Share 2 | 76.90 | 117.0 | 115.0 | 109.0 | 181.0 | 192.0 |
| Cash Flow per Share 2 | 4.830 | 7.980 | 10.10 | 8.750 | 0.2600 | 1.760 |
| Capex 1 | 258 | 89.5 | 153 | 58.5 | 148 | 709 |
| Capex / Sales | 7.32% | 2.91% | 4.66% | 1.37% | 3.18% | 13.82% |
| Announcement Date | 21-05-17 | 21-05-17 | 21-05-17 | 21-07-30 | 22-08-26 | 23-08-18 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +47.43% | 158M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- WINDLAS Stock
- Financials Windlas Biotech Limited
